Revenue has shown steady annual growth with a recent acceleration in the last two quarters, while net income has demonstrated volatility related to operating expenses and non-operating items. Operating income has rebounded following a dip in Q4 2025, underscoring improved cost control and operational leverage.

Revenue increased from $9.67 billion in 2024 to around $9.81 billion in 2025 with quarterly revenue consistently above $2.2 billion, driven primarily by increased product sales and expanding market penetration. Revenue composition benefits from diversified products but remains heavily reliant on key therapeutic categories.

Gross margins have declined slightly from ~76% to ~70% recently, indicating higher cost of goods sold pressure, while operating margins have been more volatile, impacted by fluctuations in operating expenses and other charges. EBITDA margins remain solid above 16% in the latest quarter, though down from highs near 30% previously.

Earnings displays variability due to significant other expenses and tax effects, yet the core earnings generation from operations remains strong. The recent quarters' positive surprises in EPS suggest underlying earnings strength despite headline net income sensitivity to non-operating items.

Biogen’s revenue grew approximately 1.4% year-over-year from 2025 to 2026, marked by Q2 2026 revenue increasing about 13% QoQ from $2.47 billion to $2.74 billion, signaling strong sequential improvement.

EPS jumped from a negative $0.33 in Q4 2025 to $0.66 in Q2 2026, reflecting over 300% recovery and growth, driven by operational improvements and lower expense growth. Annual EPS estimated growth around 10-15% based on trailing data.

Key growth drivers include increased sales of core neurology products, successful new product launches, and efficiencies in research and development processes. Favorable market conditions and expanding indications also support growth.

Growth is primarily organic, supported by strong product demand and pipeline progression rather than one-time events or large acquisitions, enhancing sustainability prospects.

Gross margin contracted from above 76% in 2024 to about 57% in Q2 2026, while operating margins compressed but showed signs of stabilization recently with a rebound to ~11.6% operating income margin in Q2 2026.

ROE, while not directly provided, is likely moderate given the net income margins around 3.5% in the latest quarter against a sizable equity base, suggesting room for improvement as profitability stabilizes.

Margins face challenges from competitive pricing pressure and ongoing investment requirements, but Biogen’s established market position and product mix provide resilience for medium-term sustainability.